Delivered her PhD thesis "Treatment response evaluation in experimental prostate cancer by functional magnetic resonance imaging and molecular profiling" in 2012.
Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H(2024) MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy Radiother Oncol, 195, 110263(in press) DOI 10.1016/j.radonc.2024.110263, PubMed 38556173
Lukovic J, Pintilie M, Han K, Fyles AW, Bruce JP, Quevedo R, Pugh TJ, Fjeldbo CS, Lyng H, Milosevic MF(2024) An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer Clin Cancer Res, 30(6), 1200-1207 DOI 10.1158/1078-0432.CCR-23-2085, PubMed 38180733
Gorodetska I, Offermann A, Püschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo CS, Di Gaetano S, Schwarz FM, Patil S, Borkowetz A, Erb HHH, Baniahmad A, Mircetic J, Lyng H, Löck S, Linge A, Lange T, Knopf F, Wielockx B, Krause M, Perner S, Dubrovska A(2024) ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription Theranostics, 14(2), 714-737 DOI 10.7150/thno.88057, PubMed 38169509
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@rr-research.no
